dexibuprofen arginine

JC242 is an oral tablet formulation of dexibuprofen arginine, developed by the China-Japan Friendship Hospital. Dexibuprofen is the pharmacologically active S(+)-enantiomer of the non-steroidal anti-inflammatory drug (NSAID) ibuprofen. By complexing dexibuprofen with the amino acid L-arginine, the formulation creates a highly soluble salt that facilitates rapid absorption from the gastrointestinal tract, potentially leading to a faster onset of antipyretic and analgesic effects compared to standard formulations. Its primary mechanism of action involves the non-selective inhibition of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby blocking the synthesis of prostaglandins that mediate fever, pain, and inflammation. JC242 has been evaluated in Phase 2/3 clinical trials in China for the treatment of fever associated with uncomplicated common colds or acute influenza.

Other names

arginine dexibuprofendexibuprofen L-arginine